Bayer, Algeta nab priority review for prostate cancer drug

Bayer's next big cancer prospect, radium-223 for castration-resistant prostate cancer, has won priority review status at the FDA. In-licensed from Norway's Algeta, Alpharadin is one of the pharma company's top late-stage prospects, following a string of regulatory wins on the development front. Analysts believe this treatment has good prospects at the regulatory agencies. Release | More

 

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.